Occam Places Bell Zhong as CFO at Neomorph
Neomorph, an induced proximity platform company which raised a $109 Million A round led by Deerfield, has added Bell Zhong as Chief Financial Officer.
Neomorph is focused on solving critical problems in human health through the discovery and development of innovative new medicines against “undruggable targets.”
Zhong brings nearly two decades of investment banking and corporate finance leadership experience in the healthcare and life sciences sector. Bell joins Neomorph from Raymond James where he was Managing Director covering the biotechnology sector, responsible for advising companies of all stages of development on a wide array of financing and strategic transactions. Previously, Bell spent over 13 years at J.P. Morgan, where most recently he served as Executive Director in the firm’s leading Healthcare Investment Banking practice.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.